Canada's Access to Medicines Regime: Is it Working?
Author Information
Author(s): Jillian C. Cohen-Kohler, Laura C. Esmail, André Perez Cosio
Primary Institution: University of Toronto
Hypothesis
Can Canada's Access to Medicines Regime (CAMR) effectively achieve its humanitarian objectives?
Conclusion
CAMR is symbolically meaningful but in practice, limited, and needs to be better informed of developing country needs.
Supporting Evidence
- CAMR has not resulted in any pharmaceuticals being exported to a country in need until Rwanda's recent attempt.
- The legislation is criticized for its complexity and lack of commercial incentives for the generic drug industry.
- Developing countries find CAMR overly complex and not tailored to their specific needs.
- Stakeholders expressed that the legislation does not adequately address the realities of the pharmaceutical market in developing countries.
- Many stakeholders believe that the legislation needs to prioritize public health over trade interests.
Takeaway
This study looks at whether Canada's law for exporting medicines to help developing countries actually works. It finds that while the law sounds good, it doesn't help much in reality.
Methodology
Qualitative interviews with 19 stakeholders from various sectors were conducted and analyzed for themes.
Potential Biases
Potential bias from stakeholders' vested interests in the pharmaceutical industry.
Limitations
The study focused on perceptions of CAMR without evaluating its application directly.
Participant Demographics
Stakeholders included health policymakers, government officials, representatives from the pharmaceutical industry, NGOs, and international organizations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website